Mutations in RUNX1 are found in roughly 10% of AML cases and occur in tandem with a complex array of gene mutations, including epigenetic regulators such as IDH2 and ASXL1 [75], which confer inferior prognosis [73,76,77]. Here, RUNX1 is linked to acute myeloid leukemia.